Key Points {#FPar1}
==========

A unified cefepime population pharmacokinetic model has been developed from adult and pediatric patients and evaluates well in independent populations.When paired with real-time β-lactam assays, a precision dosing approach will optimize drug exposure and improve clinical outcomes.

Introduction {#Sec1}
============

Cefepime is a commonly utilized antibiotic for nosocomial infections. Rising resistance, manifesting as increased cefepime minimum inhibitory concentrations (MICs), has led to more frequent clinical failures \[[@CR1], [@CR2]\]. To advise clinical outcomes according to MICs, the Clinical and Laboratory Standards Institute updated the susceptibility breakpoints and then created a category of susceptible-dose dependent for MICs of 4 and 8 mg/L for *Enterobacteriaceae* spp. \[[@CR3]\]. Achieving goal pharmacokinetic exposures to effectively treat these higher MICs can require a precision dosing approach.

Cefepime, like other β-lactams, has pharmacodynamic activity governed by 'time-dependent' activity. The fraction of time that the unbound drug concentration exceeds the MIC (*f*T~\>MIC~) for the dosing interval is the pharmacokinetic/pharmacodynamic (PK/PD) efficacy target for cefepime \[[@CR4]\], and a target of 60--74% has been previously proposed \[[@CR5]--[@CR8]\]. For the currently approved cefepime product and combination agents in the pipeline \[[@CR9], [@CR10]\], understanding cefepime disposition and variability is crucial to for optimal treatment of patients. As inter- and intra-patient PK variability can impact the achievement of PD goals, understanding the precision of population dosing is important. Further, to fully realize precision dosing, individualized models (e.g., Bayesian models) are needed. Once developed, these models will form the basis for adaptive feedback and control strategies when paired with real-time drug assays. The purpose of this study was to: (1) develop and evaluate a unified cefepime population PK model for adult and pediatric patients, and (2) construct an individualized model that can be utilized to deliver precision cefepime dosing.

Materials and Methods {#Sec2}
=====================

Study Populations {#Sec3}
-----------------

Data from four clinical cefepime PK studies representing unique groups of patients were compiled. Subject demographics and study methodologies have been previously described \[[@CR11]--[@CR14]\]. In brief, populations represented were febrile neutropenic adults with hematologic malignancies \[[@CR13], [@CR14]\], those with critical illness \[[@CR12]\], and children with presumed or documented bacterial infections \[[@CR11]\]. For the two studies that evaluated adults with neutropenic fever, Sime et al. prospectively enrolled 12 patients receiving chemotherapy and/or stem cell transplant who subsequently developed febrile neutropenia and were administered maximum doses of cefepime \[[@CR13]\]. A total of 53 cefepime plasma concentrations in presumably steady-state dosing intervals (third, sixth, and ninth) were analyzed for PK target attainment. Whited et al. prospectively studied similar patients (*n* = 9) who were admitted to hematology-oncology services and were receiving cefepime at a maximum dosage for febrile neutropenia \[[@CR14]\]. Cefepime PK samples were obtained during steady state and analyzed for population parameters. Critically ill adults were studied by Roberts et al. as a prospective multinational PK study and included 14 patients who received cefepime (only *n* = 13 were included for model evaluation) \[[@CR12]\]. Last, Reed et al. characterized cefepime pharmacokinetics in hospitalized pediatric patients (above 2 months of age) who received cefepime as monotherapy for bacterial infections \[[@CR11]\]. For our study, only those who received intravenous cefepime were included for model development.

Model Building Populations {#Sec4}
--------------------------

Adult (*n* = 9) and partial pediatric (*n* = 24) datasets were utilized for PK model building (Fig. [1](#Fig1){ref-type="fig"}) \[[@CR11], [@CR14]\]. Model evaluation was performed with other datasets consisting of independent adult (*n* = 12, *n* = 13) and pediatric (*n* = 12) patients \[[@CR11]--[@CR13], [@CR15]\]. Pediatric patients from Reed et al. \[[@CR11]\] were randomized into the model building or the evaluation dataset. All clinical patient-level data included age, weight, and serum creatinine. An estimated creatinine clearance (CrCL) was calculated for each patient \[[@CR16]\]. The Cockcroft--Gault formula (applied to all subjects) served as a standardized descriptor for the elimination rate constant. This study was exempted by the Institutional Review Board at Midwestern University Chicago College of Pharmacy.Fig. 1Schematic for data sources in model development and evaluation

Pharmacokinetic Models {#Sec5}
----------------------

To construct the base PK models, the nonparametric adaptive grid (NPAG) algorithm \[[@CR17], [@CR18]\] within the Pmetrics (Version 1.5.2) package \[[@CR18]\] for R \[[@CR19]\] was utilized. Multiple physiologically relevant, one- and two-compartmental PK models were built and assessed. The one-compartment structural model included an intravenous cefepime dose into and parameterized total cefepime elimination rate constant (*K*~e~) from the central compartment. The two-compartment model included additional parameterizations of intercompartmental transfer constants between central and peripheral compartments (*K*~CP~ and *K*~PC~). In candidate models, total cefepime elimination was explored according to full renal and partial renal clearance (CL) models \[i.e., non-renal elimination (*K*~e~Intcpt) and renal elimination descriptor (*K*~e~0 vectorized as a function of glomerular filtration estimates)\] \[[@CR9], [@CR20]\].

Assay error was included into the model using a polynomial equation in the form of standard deviation (SD) as a function of each observed concentration, *Y* (i.e., SD = *C*~0~ + *C*~1~ · *Y*). Observation weighting was performed using gamma (i.e., error = SD · gamma), a multiplicative variance model to account for extra process noise. Gamma was initially set at 4 with *C*~0~ and *C*~1~ equal to 0.5 and 0.15, respectively.

Covariate relationships were assessed using the 'PMStep' function in Pmetrics by applying stepwise linear regressions (forward selection and backwards elimination) of all covariates on PK parameters. Additionally, a priori analyses examined the effect of covariates on cefepime *K*~e~, and both weight and CrCL were variables considered a priori to have a high potential likelihood to impact cefepime pharmacokinetics (Table [1](#Tab1){ref-type="table"} and Fig. S2 of the Electronic Supplementary Material \[ESM\]) \[[@CR9], [@CR21], [@CR22]\]. Weight and CrCL were standardized to 70 kg and 120 mL/min, respectively. Further, an allometric scaler was applied to standardized weight (i.e., quotient of weight in kg divided by 70 kg raised to the negative 0.25th power) as a covariate adjustment to *K*~e~ (ESM). Ultimate model retention was governed according to criteria described below.Table 1Population pharmacokinetic model builds and comparisonsModelsVolume of distributionTotal elimination rate constant-2LLAICChange in OFVPopulationBayesianBiasImprecision*R*^2^BiasImprecision*R*^2^Base1-compt*V*~0~*K*~e~32233229--0.8221.30.23− 0.051.660.847Base2-compt*V*~0~*K*~e~299430042291.9141.90.280.703.870.8522-compt*V*~0~ · (WT/70)*K*~e~ · (WT/70)2990300042.1768.40.61− 0.181.120.965Final2-compt*V*~0~ · (WT/70)\[*K*~e~Intcpt + (CrCL/120) · *K*~e~0\] · (WT/70)^− 0.25^29662978340.537.750.87− 0.151.070.965− *2LL* − 2 log-likelihood, *AIC* Akaike's information criterion, *OFV* objective function value, *WT* weight in kg

The best-fit PK and error model was identified by the change in objective function value (OFV) calculated as differences in − 2 log-likelihood, with a reduction of 3.84 in OFV corresponding to *p* \< 0.05 based on Chi-square distribution and one degree of freedom. Further, the best-fit model was selected based on the rule of parsimony and the lowest Akaike's information criterion scores. Goodness of fit of the competing models were evaluated by regression on observed vs. predicted plots, coefficients of determination, and visual predictive checks. Predictive performance was assessed using bias and imprecision in both population and individual prediction models. Bias was defined as mean weighted prediction error; imprecision was defined as bias-adjusted mean weighted squared prediction error. Posterior-predicted cefepime concentrations for each study subject were calculated using individual median Bayesian posterior parameter estimates.

Model Evaluation {#Sec6}
----------------

To evaluate the final adjusted model, the NPAG algorithm \[[@CR17], [@CR18]\] was employed to assess the performance with separate data sets (Fig. [1](#Fig1){ref-type="fig"}). The population joint density from the best-fit covariate adjusted model was employed as a Bayesian prior for the randomly withheld pediatric data and separate adult data. In the evaluation process, structural model, model parameters, assay error, and observation weighting were unchanged. Goodness of fit of the competing models were determined as described above.

Simulations and Probability of Target Attainment {#Sec7}
------------------------------------------------

Simulation was performed to examine the exposures predicted by the final model, employing all support points from the population parameter joint density in the final NPAG analysis \[[@CR18], [@CR23]\]. Each support point was treated as a mean vector surrounded by the population variance--covariance matrix (i.e., covariance equal to the population covariance divided by the total number of support points). For each subject, 1000 simulated profiles were created with predicted outputs at 0.1-h intervals. Covariate values for each simulated subject were fixed based on arithmetic means of observed weight and CrCL for corresponding adult and pediatric populations. Semi-parametric Monte Carlo sampling was performed from the multimodal multivariate distribution of parameters with the parameter space concordant with the NPAG population analysis results (i.e., best-fit model) \[Table S1 of the ESM\] \[[@CR23]\]. Maximum dosing regimens were simulated for adult and pediatric populations (total *n* = 33): 2 g every 8 h infused over 0.5 h and 50 mg/kg every 8 h infused over 0.5 h, respectively. Protein binding of 20% (i.e., 80% free fraction of total cefepime dose) was accounted for in predicting cefepime concentrations \[[@CR9]\]. The PK/PD target of *f*T~\>MIC~ ≥ 68% was utilized across doubling MICs of 0.25--32 mg/L over the first 24 h of cefepime therapy \[[@CR5]\]. Estimates are provided from the first 24 h of simulations as timely administration of effective antimicrobial agents is associated with increased survival \[[@CR24]\].

Results {#Sec8}
=======

Demographics {#Sec9}
------------

A total of 70 clinically diverse subjects, contributing 683 cefepime concentrations, were included in this study (*n* = 33 subjects for model development; *n* = 37 subjects for evaluation) (Fig. [1](#Fig1){ref-type="fig"}). Adult subjects (*n* = 34), including those admitted to hematology and oncology services (*n* = 21) and intensive care units (*n* = 13), had a mean weight \[SD\] of 82.7 kg \[21.5\] and mean CrCL \[SD\] of 106.7 mL/min \[58.4\]. For the pediatric subjects (*n* = 36), means \[SD\] of weight and CrCL were 16.0 kg \[16.1\] and 195.6 mL/min \[40.5\], respectively. Adult subjects ranged in age from 22 to 82 years (mean, 55.4 years) while pediatric subjects ranged from approximately 2 months to 16 years of age (mean, 3.9 years).

Pharmacokinetic Model Selection, Parameters, and Evaluation {#Sec10}
-----------------------------------------------------------

A total of 428 cefepime observations were available for model development. Cefepime concentrations ranged from 0.5 to 249.7 μg/mL. The base one- and two-compartment models (without covariate adjustment) produced reasonable fits for observed and Bayesian posterior-predicted cefepime concentrations (*R*^2^ = 84.7% and 85.2%, respectively), but population estimates were unsatisfactory (*R*^2^ = 22.7% and 27.8%, respectively) (Table [1](#Tab1){ref-type="table"}). Weight and CrCL displayed relationships with the standard two-compartment model (i.e., base two-compartment model). Volume of distribution was associated with weight (*p* \< 0.2) and Ke (total) was associated with CrCL (*p* \< 0.2). After standardizing weight (to 70 kg) without an allometric scaler in the base two-compartment model, fits for both population and Bayesian posterior estimates against the observed data improved (*R*^2^ = 60.7% and 96.5%, respectively; OFV change, 4). Bias and imprecision for Bayesian posterior fits were − 0.18 and 1.12, respectively. When covariates (i.e., weight to volume of distribution and *K*~e~; CrCL to *K*~e~) and the allometric scaler were applied in the two-compartment model, Bayesian posteriors fit well (*R*^2^ = 96.5%; Fig. [2](#Fig2){ref-type="fig"} right) with low bias and imprecision (− 0.15 and 1.07, respectively), and the population PK model produced good fits of the observed cefepime concentrations (*R*^2^ = 87.0%, bias = 0.53, imprecision = 7.75; Fig. [2](#Fig2){ref-type="fig"} left). The OFV change from the weight-adjusted two-compartment model to the final model was significant at − 34 (*p* \< 0.05) \[Table [1](#Tab1){ref-type="table"}\].Fig. 2Goodness-of-fit plots for best-fit population cefepime PK model (model development)

The final model also produced acceptable predicted checks (Fig. [3](#Fig3){ref-type="fig"}). Thus, a two-compartment model with weight and CrCL as covariate adjustments and allometric scaling was selected as the final PK model. The population parameter values from the final PK model are summarized in Table [2](#Tab2){ref-type="table"}. Structural model and differential equations that define the population PK are listed in the ESM. The population parameter value covariance matrix can be found in Table [3](#Tab3){ref-type="table"}. Additionally, weighted residual error plots for the best-fit model (Fig. S1) and scatter plots for covariates for the base structural model (Fig. S2) can be found included in the ESM. For the evaluation subset, Bayesian priors resulted in reasonably accurate and precise predictions (population *R*^2^ = 84.0%, Bayesian *R*^2^ = 90.2%; Fig. [4](#Fig4){ref-type="fig"}).Fig. 3Visual Predictive Checks for the Best-fit PK Model. Dashed blue lines: 2.5th and 97.5th percentiles of observations; red line: median; blue shaded areas: 95% CI around the 2.5th and 97.5th percentiles of simulations; pink area: the 95% CI around the median of the simulationsTable 2Population pharmacokinetic parameter estimates from the final modelMedian (95% CI)CV (%)Shrinkage (%)*V*~0~ (L)11.172 (9.40, 12.50)22.6614.7*K*~e~Intcpt (h^−1^)0.506 (0.33, 0.71)59.2415.1*K*~e~0 (h^−1^)0.236 (0.11, 0.40)133.956.8*K*~CP~ (h^−1^)1.716 (1.02, 3.11)68.827.7*K*~PC~ (h^−1^)1.502 (1.35, 1.90)60.638.8*V*~0~ and *K*~e~Intcpt are standardized to weight (kg)/70 kg in the final structural model*K*~e~0 is standardized to weight (kg)/70 kg and creatinine clearance (mL/min)/120 mL/min in the final structural model*CI* credibility interval, *CV* coefficient of variationTable 3Population parameter value covariance matrix for the best-fit model*V*~0~*K*~e~Intcpt*K*~e~0*K*~CP~*K*~PC~*V*~0~6.366--------*K*~e~Intcpt− 0.1060.085------*K*~e~0− 0.238− 0.1520.499----*K*~CP~− 1.5760.0050.1452.354--*K*~PC~− 0.6800.027− 0.1881.4411.414Fig. 4Goodness-of-fit plots for evaluation of population cefepime PK model (model evaluation)

Simulation and Probability of Target Attainment {#Sec11}
-----------------------------------------------

Results of the probability of target attainment (PTA) analysis are shown in Table [4](#Tab4){ref-type="table"} and Fig. [5](#Fig5){ref-type="fig"} for the first 24 h of therapy. Two cefepime regimens were utilized to simulate PTA for adult and pediatric subjects. Cefepime dosage of 2 g every 8 h infused over 30 min produced PTAs of \> 90% for MICs of 0.25--2 mg/L, while a more than two-fold drop of PTA was observed from MICs of 4 mg/L to 8 mg/L. The second cefepime regimen of 800 mg every 8 h (50 mg/kg based on a population mean weight of 16.0 kg) infused over 30 min achieved a PTA of \> 90% only at an MIC of 0.25 mg/L, a PTA at 81.1% at an MIC of 0.5 mg/L and performs poorly across subsequent higher doubling MICs.Table 4Probability of target attainment at different cefepime minimum inhibitory concentrations (MICs) for the first 24 h (h) of therapy (maximum recommended dosages for adult and pediatric patients)Cefepime regimenCefepime MICs (mg/L)Dose (mg)Dosing interval (h)Infusion time (h)0.25 (%)0.5 (%)1 (%)2 (%)4 (%)8 (%)16 (%)32 (%)200080.510099.597.694.378.536.65.50.380080.593.681.175.258.833.111.41.70.3800 mg is based on 50 mg/kgFig. 5Probability of target attainment at different cefepime MICs

Discussion {#Sec12}
==========

This study created a population and individual PK model for adult and pediatric patients and can serve as a Bayesian prior for precision dosing. When paired with a real-time assay for cefepime, this model allows for precise and accurate predictions of cefepime disposition via adaptive feedback control. In the absence of real-time assays, these cefepime PK parameters facilitate more accurate population-based dosing strategies. Previous work by Rhodes et al. has shown an absolute difference of approximately 20% in survival probability across the continuum of achieving 0--100% *f*T~\>MIC~ in adult patients with Gram-negative bloodstream infections, thus understanding the dose and re-dosing interval necessary to achieve optimal PK exposures should greatly improve clinical outcomes for patients treated with cefepime \[[@CR5]\].

Individualized dosing and therapeutic drug monitoring of β-lactam antibiotics (e.g., cefepime) are critically important to achieving optimal drug exposure (i.e., optimal *f*T~\>MIC~ as the PK/PD target) and improving clinical outcomes \[[@CR4], [@CR25], [@CR26]\]. Precision medicine has been named as a major focus for the National Health Institute with \$215 million invested \[[@CR27]\], yet precision medicine has mostly focused on genomic differences \[[@CR28], [@CR29]\]. Precision dosing is an important facet of precision medicine, and renewed efforts in precision dosing in the real-world setting are being pursued \[[@CR30]\]. Cefepime is a highly relevant example. While rigorous reviews and analyses are conducted during the development phase of an antibiotic, dose optimization is far less ideal for the types of patients who ultimately receive the drug. This is highlighted by the fact that although cefepime-associated neurotoxicity is rare, this serious and potentially life-threatening adverse event has been increasingly reported and few strategies exist for optimizing and delivering precision exposures \[[@CR31], [@CR32]\]. Lamoth et al. found that a cefepime trough concentration of ≥ 22 mg/L has a 50% probability of predicting neurotoxicity \[[@CR33]\]. Huwyler et al. identified a similar predictive threshold of \> 20 mg/dL (five-fold increased risk for neurologic events) \[[@CR34]\]. In contrast, Rhodes et al. found the cut-off of 22 mg/L to be suboptimal \[[@CR35]\]. Furthermore, Rhodes et al. performed simulations from literature cefepime data and observed a high intercorrelation amongst all PK parameters (i.e., area under the curve at steady state, maximum plasma concentration, and minimum plasma concentration), suggesting that more work is needed to establish the pharmacokinetic/toxicodynamic (PK/TD) profile for cefepime.

In addition to complications by these less-than-ideal PK/TD data, clinicians are left to treat patients with extreme age differences, organ dysfunction, and comorbid conditions affecting antibiotic pharmacokinetics/pharmacodynamics \[[@CR26]\]. Further, a contemporary dose reduction strategy based on estimated renal function (e.g., estimated CrCL using the Cockcroft--Gault formula) is also likely to be confounded in these patients by intrinsic PK variability, such as changes in volume of distribution, and the challenges of accurately estimating the glomerular filtration rate at any point in time, leading to more 'uncertainties' in balancing dose optimization and adverse events \[[@CR9], [@CR36]\]. These 'real-world' patients are often under-represented, and thus not well understood, from a PK/PD and PK/TD standpoint during the drug approval process. Bridging to the more typical patients that are clinically treated is important and central to the mission of precision medicine. The findings of this study can be used to guide cefepime dosing in these 'real-world' patients.

Several other studies have reviewed population cefepime pharmacokinetics. Sime et al. observed that patients with neutropenic fever had a mean CL of 8.6 L/h and a mean elimination half-life of 2.7 h \[[@CR13]\]. Nicasio et al. studied 32 critically ill patients receiving intravenous cefepime for ventilator-associated pneumonia and observed that means of total CL and elimination half-life (as calculated from mean total CL and mean volume of distribution) were 7.6 L/h and 2.0 h, respectively \[[@CR37]\]. The noncompartmental analysis conducted (in the model development adult population) in our study produced similar results (CL, 7.59 L/h; elimination half-life, 2.98 h). Shoji et al. studied 91 pediatric patients and observed a mean of CL of approximately 1.86 L/h and a mean elimination half-life of 3.5 h \[[@CR38]\]. In our pediatric population, means of CL and elimination half-life were 3.1 L/h and 3.0 h, respectively. Our simulation findings are similar to those of Shoji et al. that the maximum pediatric cefepime dosing did not adequately achieve optimal exposure to target higher MICs. While the cefepime package labeling recommends maximum dosages of 2 g every 8 h for adult patients with neutropenic fever and 50 mg/kg every 8 h for pediatric patients with pneumonia and/or neutropenic fever, there may be a need to extend these dosing regimens to other populations (in the absence of aforementioned indications) to achieve the best clinical outcomes by optimizing the PK/PD attainment goals \[[@CR9]\].

Other studies also performed a simulation for PTA with different cefepime regimens and renal functions. Tam et al. found that with a PD target of 67% *f*T\>MIC, 2 g every 8 h (30-minute infusion) achieved approximately 90% PTA for MIC of 8 mg/L in patients with CrCL of 120 mL/min while 2 g every 12 h achieved barely above 80% PTA for an MIC of 4 mg/L in the same population \[[@CR39]\]. Nicasio et al. also conducted a simulation using a PD target of 50% *f*T\>MIC in the critically ill with varying renal function. The maximum recommended dosage (2 g every 8 h) in patients with CrCL between 50 and 120 mL/min achieved a PTA of 78.1% at an MIC of 16 mg/L; however, when the same regimen was infused over 0.5 h, the PTA achieved was significantly lower \[[@CR37]\]. Collectively, these findings suggest that cefepime exposure is highly variable and may be clinically suboptimal in a large number of patients commonly treated with cefepime. These findings support the need for precision dosing and therapeutic drug monitoring for β-lactam antibiotics to reach optimal PK/PD targets given the high variability in drug exposures.

Our study is not without limitations. Although a relatively large and diverse cohort was included in model development and evaluation, we did not specifically assess certain subgroups such as patients with morbid obesity and severe renal dysfunction. These conditions may require patient-specific models. Second, many studies to date included 'real-world' patients with various disease sates (e.g., neutropenic fever, renal failure, sepsis); however, all studies were conducted under the research protocol where doses, and administration times were all carefully confirmed. Additional efforts will be needed to evaluate model performance in clinical contexts.

Conclusions {#Sec13}
===========

A unified population model for cefepime in adult and pediatric populations was developed and demonstrated excellent performance on evaluation. Current cefepime dosages are often suboptimal, and population variability is high. Precision dosing approaches and real-time assays are needed for cefepime to optimize drug exposure and improve clinical outcomes.
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